LPAA — Launch One Acquisition Corp. Stock Price, Chart & AI Report

Positive Jan 13, 2026 • 14:51 UTC Benzinga • Globe Newswire

Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform

Minovia Therapeutics announced the grant of two new U.S. patents (No. 12,502,408 and No. 12,329,781) covering its proprietary Mitochondrial Augmentation Therapy (MAT) platform for treating primary mitochondrial diseases and renal diseases. The patents, with corresponding grants in Europe and Japan, strengthen the company's intellectual property portfolio. Minovia's lead program MNV-201, currently in clinical trials for Pearson Syndrome, consists of autologous hematopoietic stem cells enriched with placental-derived mitochondria. The company is proceeding with a business combination with Launch One Acquisition Corp., expected to close in the first half of 2026.

LPAA LPAAU LPAAW mitochondrial augmentation therapy patent grants MNV-201 Pearson Syndrome cell therapy

Sentiment note

Minovia's patent grants and clinical progress strengthen the value proposition of the pending business combination. The company's expanding IP estate and therapeutic applications support the rationale for the merger expected to close in H1 2026.

Neutral Oct 15, 2025 • 11:30 UTC Benzinga • Globe Newswire

Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics received FDA Orphan Drug Designation for MNV-201, a novel cell therapy targeting Myelodysplastic Syndrome (MDS), and announced a planned business combination with Launch One Acquisition Corp.

LPAA LPAAU LPAAW FDA Orphan Drug Designation Myelodysplastic Syndrome Mitochondrial Augmentation Technology cell therapy

Sentiment note

Participating in a planned business combination with Minovia Therapeutics, which represents a standard merger transaction

Neutral Sep 18, 2025 • 11:30 UTC Benzinga • Globe Newswire

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

Minovia Therapeutics received FDA Fast Track Designation for MNV-201, its investigational compound targeting Myelodysplastic Syndrome (MDS), potentially accelerating drug development and review process.

LPAA LPAAU LPAAW FDA Fast Track Designation Myelodysplastic Syndrome Mitochondrial Augmentation Technology cell therapy

Sentiment note

Involved in a planned business combination with Minovia Therapeutics, with transaction projected to close in late 2025

Positive Jun 25, 2025 • 12:30 UTC Benzinga • Globe Newswire

Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets

Minovia Therapeutics, a clinical-stage biotechnology company, and Launch One Acquisition Corp., a SPAC, have announced a proposed business combination to create a Nasdaq-listed mitochondrial therapy company focused on rare diseases and longevity.

LPAA LPAAU LPAAW Minovia Therapeutics Launch One Acquisition Corp. mitochondrial therapy rare diseases longevity

Sentiment note

Launch One Acquisition Corp. is a SPAC focused on healthcare innovation. The proposed business combination with Minovia Therapeutics is expected to create a publicly traded, clinical-stage biotechnology company focused on developing and commercializing Minovia's Mitochondrial Augmentation Technology platform.